会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • PROCESS FOR PREPARING DERIVATIVES OF AZABICYCLO NAPHTHYRIDINE CARBOXYLIC ACID COMPRISING A DIPEPTIDE
    • 制备包含哌啶酮的亚硫酰基萘甲酸羧酸衍生物的方法
    • WO1997000268A1
    • 1997-01-03
    • PCT/IB1996000257
    • 1996-03-27
    • PFIZER INC.BRAISH, Tamim, F.CASTALDI, Michael, J.WATSON, Harry, A., Jr.
    • PFIZER INC.
    • C07K01/06
    • C07K5/06191Y02P20/55
    • A novel process for preparing a prodrug acid, viz., 7-[(1 alpha , 6 alpha , 7 alpha )-6-(L-Ala-L-Ala-amino)-3-azabicyclo[3.1.0]hex-3-yl]-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, in the form of a pharmaceutically acceptable acid addition salt, is disclosed, which involves (1) treating an N-protected 7-[(1 alpha , 5 alpha , 6 alpha )-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid C1-C4 alkyl ester, wherein the nitrogen-protecting group is benzyloxycarbonyl, C1-C4 alkoxycarbonyl or C1-C4 alkanoyl, with a strongly-protic acid to selectively remove the N-protecting group; (2) then condensing the resulting free amino ester compound with an N-protected L-alanyl-L-alanine dipeptide compound, wherein the N-protecting group is as previously defined, in the presence of a standard dehydrating agent to form the corresponding N-protected prodrug ester compound as the desired condensation product; and (3) thereafter hydrolyzing the intermediate N-protected prodrug ester in the presence of a pharmaceutically-acceptable strong acid to convert said N-protected prodrug ester to the desired naphthyridinone L-Ala-L-Ala prodrug acid final product, in the form of the corresponding pharmaceutically acceptable acid addition salt, indicated above. The latter prodrug acid final product is especially useful in the form of the corresponding methanesulfonic acid addition salt, which serves as a water-soluble prodrug companion to a known antibacterial agent, viz., 7-[(1 alpha , 5 alpha , 6 alpha )-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1-naphthyridine-3-carboxylic acid.
    • 制备前体药物酸,即7 - [(1α,6α,7α)-6-(L-Ala-L-Ala-氨基)-3-氮杂双环[3.1.0] 吡啶-3-基] -6-氟-1-(2,4-二氟苯基)-1,4-二氢-4-氧代-1,8-二氮杂萘-3-羧酸,其为药学上可接受的酸加成盐 ,其涉及(1)处理N-保护的7 - [(1α,5α,6α)-6-氨基-3-氮杂双环[3.1.0]己-3-基] -6-氟 -1-(2,4-二氟苯基)-1,4-二氢-4-氧代-1,8-二氮杂萘-3-羧酸C1-C4烷基酯,其中氮保护基是苄氧羰基,C1-C4烷氧基羰基 或C 1 -C 4烷酰基,用强质子酸选择性除去N-保护基; (2)然后将所得游离氨基酯化合物与N-保护的L-丙氨酰-L-丙氨酸二肽化合物缩合,其中N-保护基团如前所定义,在标准脱水剂存在下形成相应的N 保护的前药酯化合物作为所需的缩合产物; 和(3)然后在药学上可接受的强酸存在下水解中间体N-保护的前药酯,以将所述N-保护的前药酯转化为所需的萘啶酮L-Ala-L-Ala前药酸最终产物,形式 的上述相应的药学上可接受的酸加成盐。 后一种前药酸最终产物特别可用于相应的甲磺酸加成盐的形式,其用作已知抗菌剂的水溶性前体药物,即7 - [(1α,5α,6α 基)-6-氨基-3-氮杂双环[3.1.0]己-3-基] -6-氟-1-(2,4-二氟苯基)-1,4-二氢-4-氧代-1-萘-3- -羧酸。